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The trans-resveratrol (RSV) has been reported to act as an antiproliferative and chemopreventive 
agent against a wide variety of tumors, including prostate cancer (PCa)I,2. Nanoencapsulation of 
RSV represents a powerful strategy to provide protection of degradation, enhancement of 
bioavailability, improvement of intracellular penetration and control delivery,4. 
We developed novel polymeric nanoparticles (NPs) encapsulating RSV (nano-RSV), based on a 
polymeric blend, as effective prototypes for PCa treatment. NPs were characterized in terms of 
morphology, encapsulation efficiency, and in vitro release studies. Moreover, cellular uptake and 
antiproliferative efficacy ofnano-RSV in PC-3, DU-145, and LNCaP cell lines, were evaluated. 
RSV was successfully loaded in NPs with an average diameter of 150 nm and encapsulation 
efficiencies ranging from 74% to 98%. NPs are able to control the RSV release at pH 6.5 and 7.4, 
with only 55% of RSV released within 7 h. On the other hand, in gastrointestinal simulated fluids, 
NPs released about 55% of RSV in the flfst 2 h in acidic medium, and their total RSV content 
within the subsequent 5 h at pH 7.4. Confocal fluorescence microscopy revealed that NPs were 
efficiently taken up by PCa cell lines. Furthermore, nano-RSV significantly improved the 
cytotoxicity than that of free RSV in all tested cell lines, both at 10 J.1M and 20 J.1M concentrations. 
Our results support the potential use of these prototypes for the controlled delivery ofRSV for PCa 
treatment. 
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